ADVERUM BIOTECHNOLOGIES, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 6th, 2019 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Leone Patterson (“Executive”) and Adverum Biotechnologies, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).
Re: Amended and Restated Employment TermsLetter Agreement • March 6th, 2019 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
This letter agreement (the “Agreement”) sets forth the amended and restated terms of your employment with Adverum Biotechnologies, Inc. (the “Company”). These terms became effective on October 18, 2018, and shall supersede and replace the terms set forth in your earlier offer letter from the Company dated May 31, 2016.
EXCLUSIVE LICENSE AND BAILMENT AGREEMENT BETWEEN AVALANCHE BIOTECHNOLOGIES, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FORExclusive License and Bailment Agreement • March 6th, 2019 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
This exclusive license agreement (“Agreement”) is effective June 17, 2013 (“Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607- 5200, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347 (“REGENTS”) and AVALANCHE BIOTECHNOLOGIES, INC., a Delaware corporation having a principal place of business at 665 Third Street, Suite 250, San Francisco, CA 94107 (“LICENSEE”). The parties agree as follows:
LICENSE AGREEMENTLicense Agreement • March 6th, 2019 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (the “Agreement”) dated October 12, 2011 (the “Effective Date”), is between Virovek, Inc., a Delaware corporation (“Virovek”) with an address at 3521 Investment Boulevard, Suite 1, Hayward, California 94545, and Avalanche Biotechnologies, Inc., a Delaware corporation (“Avalanche”) with an address at 665 Third Street, Suite 250, San Francisco, California 94107. Virovek and Avalanche shall each be a “Party” and together shall be the “Parties”.
CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • March 6th, 2019 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
Agreement, dated as of November 5, 2014 (the “Severance Agreement”), by and between Mehdi Gasmi, Ph.D. (“Executive”) and Avalanche Biotechnologies, Inc. (the “Company”) is made as of August 21, 2015 (the “Amendment Effective Date”). Any capitalized term not defined in this Amendment shall have the meaning set forth in the Severance Agreement.
